

**IN THE EUROPEAN PATENT OFFICE  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY (IPEA/EP)**

In Re International Application of:  
  
CORCEPT THERAPEUTICS, INC.

International Application No.: PCT/US2005/008049

International Filing Date: 09 March 2005 (09.03.2005)

For: FUSED RING AZADECALIN  
GLUCOCORTICOID RECEPTOR  
MODULATORS

Authorized Officer: I. Seelmann

**STATEMENT UNDER  
ARTICLE 34(2)(d) IN REPLY  
TO WRITTEN OPINION**

European Patent Office  
D-80298 Munich  
GERMANY

Attn: IPEA/EP

Dear Sir or Madam:

In response to the Written Opinion of the International Preliminary Examining Authority (IPEA/EP), mailed 15 June 2005, Applicants submit the following remarks for consideration by the Authorized Officer under PCT Article 34 (2)(d).

**REMARKS**


**Novelty**

In the opinion of the Examining Officer, claims 1-11, 14, 20-22, 27, and 32 are anticipated by D2 (EP-A-0 375 210). More specifically, according to the Examining Officer, the generic formula of Applicants' claim 1 overlaps with the generic formula disclosed in D2 overlaps encompasses D2 Examples 2-4.

Applicants have amended claim 1 by deleting "hydrogen" from the definition of R<sup>1</sup>. Because the X and Y substituents of the generic formula disclosed in D2 are defined as "hydrogen or together are =O," amended claim 1 does not overlap with the D2 generic formula. See D2, page 3, line 25. Moreover, amended claim 1 does not encompass D2 Examples 2-4.

Therefore, because D2 does not disclose any specific compounds or generic formulae falling within the scope of amended claim 1, Applicants respectfully submit that amended claim 1, as well as claims 2-32, are novel

Respectfully submitted,

  
Kenneth E. Jenkins, PhD  
Reg. No. 51,846

Date: 06 January 2006

TOWNSEND and TOWNSEND and CREW LLP  
12730 High Bluff Drive, Suite 400  
San Diego, California 92130  
Tel: (858) 350-6100  
Fax: (858) 350-6111

60670344 v1